Auranofin shows promise as a novel anticancer agent by inhibiting key survival pathways
This research found that Auranofin (AF) induces apoptosis and cell cycle arrest in myeloma cells by inhibiting the JAK2/STAT3 signaling pathway and NF-κB activity, leading to decreased expression of the anti-apoptotic protein Mcl-1. AF’s ability to activate caspase pathways and suppress cell proliferation suggests its potential as a novel therapeutic agent for multiple myeloma, with plans for clinical trials to evaluate its efficacy in patients with relapsed or refractory disease. Given its established use in treating rheumatoid arthritis with minimal side effects, AF shows promise for repurposing as an anticancer treatment.
https://www.sciencedirect.com/science/article/abs/pii/S0145212610002559?via%3Dihub
